- Drug Class
- Calcium Channel Blocker (Non-Dihydropyridine)
- Mechanism of Action (MOA)
- Blocks L-type Ca²⁺ channels in myocardium & AV node → ↓ heart rate, ↓ AV conduction, ↓ contractility.
- Clinical Notes
- Rate control in AFib/SVT. Avoid combining with β-blockers (additive bradycardia/AV block) and in HFrEF (negative inotrope).
Sources
Reviewed September 2026- FDA label — FDA / DailyMed
Checked against the guideline or standard reference the exam keys to. If it has moved, use Report an error below.
All pharmacology